- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Childhood Sexual Abuse Litigation
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Restructuring and Business Bankruptcy
- Wealth Planning, Administration, and Disputes
- Litigation Support Services
-
December 4, 2019State of Minnesota Sues JUUL
-
November 26, 2019Minnesota Lawyer Honors Two Robins Kaplan Attorneys as 2019 Attorneys of the Year
-
November 21, 2019Firm, Attorney Stacey Slaughter Recognized by National Law Journal
-
January 10, 2020Bridgeport 2020 Consumer Class Action Litigation Conference
-
January 15-17, 2020Loss Executives Association 89th Annual Meeting and Mid-Winter Educational Program
-
January 28, 2020Boston 1L Diversity Summer Associate Program Reception
-
November 2019CLASS ACTION: Experts weigh in on significant class action developments
-
November 15, 20192019 Case Developments: Are Massachusetts Insurers Required To Be Perfect In An Imperfect World?
-
November 15, 2019Artificial Intelligence v. General Data Protection Regulation: Complex Risks in Changing Times
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
New ANDA Cases
Summer 2018
| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Indivior Inc. v. Alvogen Pine Brook LLC, 18-5285 (D.N.J.) | Apr. 3, 2018 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,931,305 |
| Indivior Inc. v. Dr. Redy’s Labs., Inc., 18-5288 (D.N.J.) | Apr. 3, 2018 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,931,305 |
| Indivior Inc. v. Par Pharm., Inc., 18-5293 (D.N.J.) | Apr. 3, 2018 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,931,305 |
| Indivior Inc. v. Teva Pharms. USA, Inc., 18-5300 (D.N.J.) | Apr. 3, 2018 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,931,305 |
| Egalet US, Inc. v. Teva Pharms. USA, Inc., 18-0505 (D. Del.) | Apr. 4, 2018 | Hon. Gregory M. Sleet | Arymo® (morphine sulfate extended-release tablets) | 9,044,402 |
| Eli Lilly and Co. v. Apotex, Inc., 18-1037 (S.D. Ind.) | Apr. 4, 2018 | Hon. William T. Lawrence | Forteo® (teriparatide for injection) | 7,517,334 |
| Eli Lilly and Co. v. Apotex, Inc., 18-0518 (D. Del.) | Apr. 5, 2018 | Hon. Leonard P. Stark | Forteo® (teriparatide for injection) | 7,517,334 |
| Senju Pharm. Co., Ltd. v. Amneal Pharms. LLC, 18-5571 (D.N.J.) | Apr. 5, 2018 | Hon. Brian R. Martinotti | Prolensa® (bromfenac ophthalmic solution) | 8,129,431 8,669,290 8,754,131 8,871,813 8,927,606 9,144,609 9,517,220 9,561,277 |
| Mylan Pharms. Inc. v. Bristol-Myers Squibb Co., IPR2018-00892 (PTAB) | Apr. 5, 2018 | N/A | Eliquis® (apixaban tablets) | 9,326,945 |
| iCeutica Pty Ltd. v. Teva Pharms. USA, Inc., 18-0525 (D. Del.) | Apr. 6, 2018 | Vacant Judgeship (2017) | Vivlodex® (meloxicam capsules) | 9,526,734 9,649,318 9,808,468 |
| Dr. Reddy’s Labs. Inc. v. Pozen Inc., IPR2018-00894 (PTAB) | Apr. 6, 2018 | N/A | Vimovo® (esomeprazole magnesium / naproxen delayed-release tablets) | 9,220,698 |
| Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., 18-5752 (D.N.J.) | Apr. 9, 2018 | Hon. Jose L. Linares | Narcan® (naloxone HCl nasal spray) | 9,480,644 9,707,226 |
| Eli Lilly and Co. v. Sunshine Lake Pharma Co., Ltd., 18-5765 (D.N.J.) | Apr. 9, 2018 | Hon. William H. Walls | Cialis® (tadalafil tablets) | 6,943,166 |
| Mitsubishi Tanabe Pharma Corp. v. Prinston Pharm. Inc., 18-6112 (D.N.J.) | Apr. 11, 2018 | Hon. Freda L. Wolfson | Invokana® (canagliflozin tablets) | 7,943,788 |
| Dr. Reddy’s Labs., Inc. v. GlaxoSmithKline LLC, 18-0548 (D. Del.) | Apr. 12, 2018 | Hon. Leonard P. Stark | Lamictal XR® (lamotrigine extended-release tablets) | 8,637,512 9,144,547 |
| Celgene Corp. v. Dr. Reddy’s Labs., Ltd., 18-6378 (D.N.J.) | Apr. 12, 2018 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 6,315,720 6,561,977 6,755,784 8,315,886 8,626,531 |
| Shire Development LLC v. Impax Labs., Inc., 18-0549 (D. Del.) | Apr. 13, 2018 | Hon. Richard G. Andrews | Mydayis® (dextroamphetamine saccharate / amphetamine aspartate monohydrate / dextroamphetamine sulfate / amphetamine sulfate extended-release capsules) | 6,913,768 8,846,100 9,173,857 |
| IBSA Institut Biochimique, S.A. v. Teva Pharms. USA, Inc., 18-0555 (D. Del.) | Apr. 13, 2018 | Hon. Leonard P. Stark | Tirosint® (levothyroxine sodium capsules) | 7,691,411 7,723,390 |
| UCB, Inc. v. Apotex Inc., 18-60846 (S.D. Fla.) | Apr. 17, 2018 | Hon. Marcia G. Cooke | Xyzal Allergy 24HR® (levocetirizine dihydrochloride solution) | 8,633,194 |
| Acerta Pharma B.V. v. Pharmacyclics LLC, 18-581 (D. Del.) | Apr. 18, 2018 | Vacant Judgeship (2017) | Calquence® (acalabrutinib capsules) Imbruvica® (ibrutinib capsules) |
7,459,554 |
| Biogen Int’l GmbH v. Banner Life Sciences LLC, 18-0582 (D. Del.) | Apr. 18, 2018 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) Bafiertam® (dimethyl fumarate delayed-release capsules) |
7,320,999 8,399,514 |
| UCB, Inc. v. Apotex Inc., 18-3404 (S.D.N.Y.) | Apr. 18, 2018 | Hon. J. Paul Oetken | Xyzal Allergy 24HR® (levocetirizine dihydrochloride solution) | 8,633,194 |
| Onyx Therapeutics, Inc. v. Cipla Ltd., 18-0598 (D. Del.) | Apr. 20, 2018 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,417,042 7,737,112 8,207,125 8,207,126 8,207,127 |
| iCeutica Pty Ltd. v. Novitium Pharma LLC, 18-0599 (D. Del.) | Apr. 20, 2018 | Vacant Judgeship (2017) | Vivlodex® (meloxicam capsules) | 9,526,734 9,649,318 9,808,468 |
| Amneal Pharms. LLC v. Alkermes Pharma Ireland Ltd., IPR2018-00943 (PTAB) | Apr. 20, 2018 | N/A | Vivitrol® (naltrexone extended-release suspension) | 7,919,499 |
| Eisai Co., Ltd. v. Bionpharma Inc., 18-0618 (D. Del.) | Apr. 24, 2018 | Hon. Leonard P. Stark | Banzel® (rufinamide tablets) | 6,740,669 7,750,028 |
| Jazz Pharms., Inc. v. Lupin Ltd., 18-8267 (D.N.J.) | Apr. 24, 2018 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 9,486,426 |
| Biogen Int’l GmbH v. Zydus Pharms. (USA) Inc., 18-0623 (D. Del.) | Apr. 25, 2018 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 |
| Biogen Int’l GmbH v. Zydus Pharms. (USA) Inc., 18-8323 (D.N.J.) | Apr. 25, 2018 | Hon. Brian R. Martinotti | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 |
| Celgene Corp. v. Zydus Pharms. (USA) Inc., 18-8519 (D.N.J.) | Apr. 27, 2018 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,977,357 8,193,219 8,431,598 |
| Sun Pharm. Indus. Ltd. v. Saptalis Pharms., LLC, 18-0648 (D. Del.) | Apr. 30, 2018 | Vacant Judgeship (2017) | Riomet® (metformin HCl oral solution) | 6,890,957 |
| Vanda Pharms. Inc. v. Teva Pharms. USA, Inc., 18-0651 (D. Del.) | Apr. 30, 2018 | Vacant Judgeship (2017) | Hetlioz® (tasimelteon capsules) | RE46,604 9,060,995 9,539,234 9,549,913 9,730,910 9,855,241 |
| Sun Pharm. Indus. Ltd. v. Saptalis Pharms., LLC, 18-2545 (E.D.N.Y.) | Apr. 30, 2018 | Hon. Joan M. Azrack | Riomet® (metformin HCl oral solution) | 6,890,957 |
| AstraZeneca AB v. Zydus Pharms. (USA) Inc., 18-0664 (D. Del.) | 1-May-18 | Hon. Richard G. Andrews | Farxiga® (dapagliflozin tablets) | 6,414,126 6,515,117 |
| H. Lundbeck A/S v. Sigmapharm Labs., LLC, 18-0671 (D. Del.) | 3-May-18 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 7,144,884 8,476,279 8,722,684 8,969,355 9,227,946 9,861,630 |
| H. Lundbeck A/S v. Torrent Pharms. Ltd., 18-0672 (D. Del.) | 3-May-18 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 9,861,630 |
| AstraZeneca AB v. Zydus Pharms. (USA) Inc., 18-8778 (D.N.J.) | 3-May-18 | Hon. Freda L. Wolfson | Farxiga® (dapagliflozin tablets) | 6,414,126 6,515,117 |
| H. Lundbeck A/S v. Sigmapharm Labs., LLC, 18-1880 (E.D. Pa.) | 4-May-18 | Hon. Juan R. Sanchez | Trintellix® (vortioxetine hydrobromide tablets) | 7,144,884 8,476,279 8,722,684 8,969,355 9,227,946 9,861,630 |
| Vanda Pharms. Inc. v. Apotex Inc., 18-689 (D. Del.) | 7-May-18 | Vacant Judgeship (2017) | Hetlioz® (tasimelteon capsules) | RE46,604 9,060,995 9,539,234 9,549,913 9,730,910 9,855,241 |
| Vanda Pharms. Inc. v. MSN Pharms. Inc., 18-690 (D. Del.) | 7-May-18 | Vacant Judgeship (2017) | Hetlioz® (tasimelteon capsules) | RE46,604 9,060,995 9,539,234 9,549,913 9,730,910 9,855,241 |
| Noven Pharms., Inc. v. Amneal Pharms. LLC, 18-0699 (D. Del.) | 8-May-18 | Hon. Leonard P. Stark | Minivelle® (estradiol transdermal system) | 9,730,900 9,724,310 9,833,419 |
| Celgene Corp. v. Cipla Ltd., 18-8964 (D.N.J.) | 8-May-18 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,977,357 8,193,219 8,431,598 |
| Sun Pharm. Indus., Inc. v. Perrigo Co., 18-0703 (D. Del.) | 9-May-18 | Vacant Judgeship (2017) | Ultravate® (halobetasol propionate lotion) | 8,962,028 |
| Sun Pharm. Indus., Inc. v. Perrigo Co., 18-0530 (W.D. Mich.) | 10-May-18 | Hon. Janet T. Neff | Ultravate® (halobetasol propionate lotion) | 8,962,028 |
| Adamas Pharma, LLC v. Sandoz Inc., 18-9032 (D.N.J.) | 10-May-18 | Hon. Brian R. Martinotti | Gocovri® (amantadine HCl extended-release capsules) | 8,389,578 8,796,337 8,889,740 8,895,614 8,895,615 8,895,616 8,895,617 8,895,618 8,741,343 9,867,791 9,867,792 9,867,793 9,877,933 |
| Eli Lilly and Co. v. Amneal Pharms. LLC, 18-9071 (D.N.J.) | 10-May-18 | Hon. William H. Walls | Cialis® (tadalafil tablets) | 6,943,166 |
| H. Lundbeck A/S v. Cipla Ltd., 18-0753 (D. Del.) | 17-May-18 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 9,861,630 |
| Astellas Pharma Inc. v. Eugia Pharma Specialties Ltd., 18-0757 (D. Del.) | 17-May-18 | Hon. Gregory M. Sleet | Xtandi® (enzalutamide capsules) | 7,709,517 8,183,274 9,126,941 |
| Noven Pharms., Inc. v. Actavis Labs. UT, Inc., 18-0758 (D. Del.) | 17-May-18 | Hon. Leonard P. Stark | Minivelle® (estradiol transdermal system) | 9,730,900 9,724,310 9,833,419 |
| Impax Labs., Inc. v. Actavis Labs FL, Inc., 18-9347 (D.N.J.) | 17-May-18 | Hon. Stanley R. Chesler | Rytary® (levodopa / carbidopa extended-release capsules) | 9,901,640 |
| Gilead Sciences, Inc. v. Aurobindo Pharma Ltd., 18-0765 (D. Del.) | 18-May-18 | Hon. Joseph F. Bataillon | Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) | 6,642,245 6,703,396 |
| Mylan Technologies, Inc. v. Noven Pharms., Inc., IPR2018-01119 (PTAB) | 18-May-18 | N/A | Minivelle® (estradiol transdermal system) | 9,833,419 |
| Bial – Portela & Ca S.A. v. SPH Shanghai Zhongxi Pharm. Co., Ltd., 18-0775 (D. Del.) | 21-May-18 | Vacant Judgeship (2017) | Aptiom® (eslicarbazepine acetate tablets) | 5,753,646 8,372,431 9,206,135 9,566,244 9,643,929 9,750,747 9,763,954 |
| H. Lundbeck A/S v. Lupin Ltd., 18-0777 (D. Del.) | 21-May-18 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 9,861,630 |
| Promius Pharma LLC v. Perrigo UK Finco Ltd Partnership, 18-0219 (E.D. Tex.) | 22-May-18 | Hon. Robert W. Schroeder, III | Sernivo® (betamethasone dipropionate spray) | 9,364,485 9,433,630 9,439,911 9,655,907 9,775,851 9,877,974 |
| Promius Pharma LLC v. Perrigo UK Finco Ltd Partnership, 18-1415 (D. Minn.) | 23-May-18 | Hon. Susan R. Nelson | Sernivo® (betamethasone dipropionate spray) | 9,439,911 9,655,907 9,775,851 9,877,974 |
| Promius Pharma LLC v. Taro Pharms., Inc, 18-4576 (S.D.N.Y.) | 23-May-18 | Hon. Alvin K. Hellerstein | Sernivo® (betamethasone dipropionate spray) | 9,364,485 9,433,630 9,439,911 9,655,907 9,775,851 9,877,974 |
| Janssen Products, L.P. v. Dr. Reddy’s Labs., Inc., 18-9655 (D.N.J.) | 24-May-18 | Hon. William H. Walls | Prezista® (darunavir tablets) | 8,518,987 7,126,015 7,595,408 |
| Mylan Pharms. Inc. v. Bayer Intellectual Property GmbH, IPR2018-01143 (PTAB) | 24-May-18 | N/A | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Pfizer Inc. v. Apotex, Inc., 18-0795 (D. Del.) | 25-May-18 | Hon. Leonard P. Stark | Inlyta® (axitinib tablets) | 8,791,140 |
| Shire Development LLC v. SpecGx LLC, 18-0800 (D. Del.) | 25-May-18 | Hon. Richard G. Andrews | Mydayis® (dextroamphetamine saccharate / amphetamine aspartate monohydrate / dextroamphetamine sulfate / amphetamine sulfate extended-release capsules) | 6,913,768 8,846,100 9,173,857 |
| Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., 18-9880 (D.N.J.) | 30-May-18 | Hon. Jose L. Linares | Narcan® (naloxone HCl nasal spray) | 9,775,838 |
| Par Pharm., Inc. v. Eagle Pharms. Inc., 18-0823 (D. Del.) | 31-May-18 | Vacant Judgeship (2017) | Vasostrict® (vasopressin injection) | 9,375,478 9,687,526 9,744,209 9,744,239 9,750,785 9,937,223 |
| Fresenius Kabi USA, LLC v. Eurohealth Int’l Sarl, 18-0835 (D. Del.) | 1-Jun-18 | Hon. Leonard P. Stark | Dilaudid® (hydromorphone HCl for injection) | 9,731,082 9,248,229 |
| Cipla Ltd. v. Eli Lilly and Co., 18-1671 (S.D. Ind.) | 1-Jun-18 | Hon. Jane Magnus-Stinson | Cialis® (tadalafil tablets) | 6,821,975 7,182,958 |
| Astellas Pharma Inc. v. Cipla Ltd., 18-0844 (D. Del.) | 5-Jun-18 | Hon. Richard G. Andrews | VESIcare® (solifenacin succinate tablets) | 6,017,927 |
| Cipla Ltd. v. Alcon Research, Ltd., IPR2018-01020 (PTAB) | 5-Jun-18 | N/A | Pazeo® (olopatadine HCl ophthalmic solution) | 8,791,154 |
| Cipla Ltd. v. Alcon Research, Ltd., IPR2018-01021 (PTAB) | 5-Jun-18 | N/A | Pazeo® (olopatadine HCl ophthalmic solution) | 9,533,053 |
| H. Lundbeck A/S v. MSN Labs. Private Ltd., 18-0853 (D. Del.) | 7-Jun-18 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 9,861,630 |
| Purdue Pharma L.P. v. Ascent Pharms., Inc., 18-0855 (D. Del.) | 7-Jun-18 | Hon. Richard G. Andrews | OxyContin® (oxycodone HCl extended-release tablets) | 9,060,976 9,073,933 9,522,919 9,147,533 9,861,582 8,309,060 9,675,610 |
| Teijin Ltd. v. MSN Labs. Private Ltd., 18-0881 (D. Del.) | 14-Jun-18 | Vacant Judgeship (2017) | Uloric® (febuxostat tablets) | 7,361,676 8,372,872 9,107,912 |
| Celgene Corp. v. Synthon Pharms. Inc., 18-10775 (D.N.J.) | 19-Jun-18 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 8,198,262 8,673,939 8,735,428 8,828,427 |
| Celgene Corp. v. Synthon Pharms. Inc., 18-0540 (M.D.N.C.) | 21-Jun-18 | Hon. Loretta C. Biggs | Pomalyst® (pomalidomide capsules) | 8,198,262 8,673,939 8,735,428 8,828,427 |
| Astellas Pharma Inc. v. Aurobindo Pharma Ltd., 18-0932 (D. Del.) | 25-Jun-18 | Hon. Richard G. Andrews | VESIcare® (solifenacin succinate tablets) | 6,017,927 |
| Celgene Corp. v. Sandoz Inc., 18-11026 (D.N.J.) | 26-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,208,516 7,427,638 7,659,302 7,893,101 8,455,536 8,802,717 9,018,243 9,872,854 |
| Celgene Corp. v. Mankind Pharma Ltd., 18-11081 (D.N.J.) | 26-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 7,893,101 |
| Gilead Sciences, Inc. v. Strides Pharma, Inc., 18-11134 (D.N.J.) | 27-Jun-18 | Hon. Michael A. Shipp | Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) | 6,642,245 6,703,396 8,592,397 8,716,264 9,457,036 9,744,181 |
| Celgene Corp. v. Torrent Pharms. Ltd., 18-11156 (D.N.J.) | 27-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 7,893,101 9,872,854 |
| Celgene Corp. v. Shilpa Medicare Ltd., 18-11157 (D.N.J.) | 27-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 7,893,101 9,872,854 |
| Celgene Corp. v. Glenmark Pharms. Ltd., 18-11158 (D.N.J.) | 27-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,208,516 7,427,638 7,659,302 7,893,101 8,455,536 8,802,717 9,018,243 9,872,854 |
| Amgen Inc. v. Accord Healthcare, Inc., 18-0956 (D. Del.) | 28-Jun-18 | Unassigned Judge | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| Celgene Corp. v. Macleods Pharms. Ltd., 18-11212 (D.N.J.) | 28-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 |
| Celgene Corp. v. MSN Labs. Private Ltd., 18-11213 (D.N.J.) | 28-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 |
| Celgene Corp. v. Teva Pharms. USA, Inc., 18-11215 (D.N.J.) | 28-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,208,516 7,427,638 7,659,302 7,893,101 8,455,536 8,802,717 9,018,243 9,872,854 |
| Celgene Corp. v. Prinston Pharm. Inc., 18-11216 (D.N.J.) | 28-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 |
| Celgene Corp. v. Emcure Pharms. Ltd., 18-11218 (D.N.J.) | 28-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 9,872,854 |
| Celgene Corp. v. Aurobindo Pharma Ltd., 18-11219 (D.N.J.) | 28-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,208,516 7,427,638 7,659,302 7,893,101 8,455,536 8,802,717 9,018,243 9,872,854 |
| Celgene Corp. v. Annora Pharma Private Ltd., 18-11220 (D.N.J.) | 28-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 9,872,854 |
| Otsuka Pharm. Co., Ltd. v. Alkem Labs. Ltd., 18-0972 (D. Del.) | 29-Jun-18 | Hon. Richard G. Andrews | Samsca® (tolvaptan tablets) | 8,501,730 |
| Amgen Inc. v. Accord Healthcare, Inc., 18-0575 (M.D.N.C.) | 29-Jun-18 | Hon. William L. Osteen, Jr. | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| AstraZeneca Pharms. LP v. Apotex Inc., 18-11238 (D.N.J.) | 29-Jun-18 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant for injection) | 6,774,122 7,456,160 8,329,680 8,466,139 |
| Celgene Corp. v. Cipla Ltd., 18-11262 (D.N.J.) | 29-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,208,516 7,427,638 7,659,302 7,893,101 8,455,536 8,802,717 9,018,243 9,872,854 |
| Celgene Corp. v. Alkem Labs. Ltd., 18-11265 (D.N.J.) | 29-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,427,638 7,659,302 7,893,101 8,455,536 9,018,243 |
| Celgene Corp. v. Zydus Pharms. USA, Inc., 18-11267 (D.N.J.) | 29-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,427,638 7,659,302 7,893,101 8,455,536 9,018,243 |
| Celgene Corp. v. Unichem Labs., Ltd., 18-11268 (D.N.J.) | 29-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,427,638 7,659,302 7,893,101 8,455,536 9,018,243 |
| Celgene Corp. v. Dr. Reddy’s Labs., Inc., 18-11269 (D.N.J.) | 29-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,427,638 7,659,302 7,893,101 8,455,536 9,018,243 |
GENERICally Speaking Summer 2018
Related Professionals
Oren D. Langer
Partner
Jeffrey Alan Hovden
Partner
Andrew J. Kabat
Associate
Kelsey J. McElveen
Associate
Christopher A. Pinahs
Associate
Related Publications
August 29, 2019
Allergan Sales, LLC v. Sandoz, Inc
GENERICally Speaking Fall 2019
September 19, 2019
Amgen Inc. v. Amneal Pharms. LLC
GENERICally Speaking Fall 2019
November, 2019
ANDA Approvals
GENERICally Speaking Fall 2019
November, 2019
ANDA Litigation Settlements
GENERICally Speaking Fall 2019
July 17, 2019
Bausch Health Cos. v. Actavis Labs. FL
GENERICally Speaking Fall 2019
Related News
September 27, 2018
August 2, 2018
January 11, 2016
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.